{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:23:57Z","timestamp":1771007037268,"version":"3.50.1"},"reference-count":39,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor lapatinib is approved for treating advanced HER2-positive breast cancer and can prevent estrogen receptor (ER)-negative mammary tumors in HER2 transgenic mouse models. Ki-67 labeling index (LI) has prognostic and predictive value and can be used to screen drugs' therapeutic and preventive potential in a clinical model of short-term presurgical therapy of breast cancer. We conducted a randomized, placebo-controlled trial of lapatinib (1500 mg\/d) administered orally for three weeks between biopsy and surgery in 60 women with HER-2\u2013positive breast cancer to assess lapatinib biomarker (including the primary endpoint, Ki-67 LI) and clinical activity in invasive breast cancer, adjacent ductal intraepithelial neoplasia (DIN, which comprises ductal carcinoma in situ and atypical ductal hyperplasia), and distant ductal hyperplasia without atypia (DH). Ki-67 LI increased progressively in association with disease stage, increasing in the placebo arm, for example, by medians of 3% in DH to 20% in DIN to 30% in invasive cancer. Ki-67 LI in cancer tissue decreased by a mean (\u00b1SD) of 9.3% (\u00b134.2) in the lapatinib arm and increased by 15.1% (\u00b130.9) in the placebo arm (P = 0.008). Compared with placebo, lapatinib reduced Ki-67 significantly more in ER-negative tumors (by 34.8%; P = 0.01) but not significantly more in ER-positive tumors (by 12.3%; P = 0.2) and reduced Ki-67 more (nonsignificantly) in cytosol PTEN-overexpressing tumors (P = 0.057). The prevalence of DIN in post-treatment surgical specimens of both arms was similar (70%\u201376%), with a median Ki-67 of 15% (range, 5%\u201335%) on lapatinib versus 20% (5%\u201360%) on placebo (P = 0.067). The prevalence of DH also was similar in both arms (&amp;gt;90%), with a median Ki-67 of 1% (1%\u20137%) on lapatinib versus 3% (1%\u20135%) on placebo (P = 0.006). Other results of lapatinib versus placebo, respectively, were as follows: Median tumor diameter at surgery of 18 mm (11 mm\u201357 mm) versus 24 mm (10 mm\u201337 mm; P = 0.009); partial response of 13.6% versus 3.7%, stable disease of 59.1% versus 40.7%, and progression of 27.3% versus 55.6% (P-trend = 0.035). In conclusion, short-term lapatinib decreased cell proliferation in DIN, DH, and invasive HER-2\u2013positive (especially ER-negative) breast cancer, thus providing the rationale for further clinical development of lapatinib for breast cancer prevention in high-risk patients, including those with HER-2\u2013positive DIN. Cancer Prev Res; 4(8); 1181\u20139. \u00a92011 AACR.<\/jats:p>","DOI":"10.1158\/1940-6207.capr-10-0337","type":"journal-article","created":{"date-parts":[[2011,6,18]],"date-time":"2011-06-18T02:28:07Z","timestamp":1308364087000},"page":"1181-1189","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Lapatinib Activity in Premalignant Lesions and HER-2\u2013Positive Cancer of the Breast in a Randomized, Placebo-Controlled Presurgical Trial"],"prefix":"10.1158","volume":"4","author":[{"given":"Andrea","family":"DeCensi","sequence":"first","affiliation":[{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"},{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Puntoni","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"},{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliana","family":"Guerrieri-Gonzaga","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Lazzeroni","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"},{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Serrano","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debora","family":"Macis","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harriet","family":"Johansson","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriana","family":"Pala","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Luini","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Veronesi","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"},{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Galimberti","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Dotti","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Viale","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"},{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Bonanni","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Divisions of 1Cancer Prevention and Genetics, 2Pathology, and 3Breast Surgery, European Institute of Oncology; 4University of Milan School of Medicine, Milan; 5Medical Oncology Unit, E.O. Ospedali Galliera, Genoa; 6University of Rome Tor Vergata, School of Medicine, Rome; and 7Medical Affair, Oncology Unit, Glaxo Smith Kline, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2011,8,3]]},"reference":[{"key":"2022060816053851900_bib1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","article-title":"Ki67 in breast cancer: prognostic and predictive potential","volume":"11","author":"Yerushalmi","year":"2010","journal-title":"Lancet Oncol"},{"key":"2022060816053851900_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jnci\/djk020","article-title":"Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer","volume":"99","author":"Dowsett","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2022060816053851900_bib3","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/jnci\/djn309","article-title":"Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics","volume":"100","author":"Ellis","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2022060816053851900_bib4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdq427","article-title":"Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer","volume":"22","author":"DeCensi","year":"2010","journal-title":"Ann Oncol"},{"key":"2022060816053851900_bib5","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jnci\/95.11.779","article-title":"A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers","volume":"95","author":"Decensi","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2022060816053851900_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/978-3-642-55647-0_10","article-title":"HRT opposed to low-dose tamoxifen (HOT study): rationale and design","volume":"163","author":"Decensi","year":"2003","journal-title":"Recent Results Cancer Res"},{"key":"2022060816053851900_bib7","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1200\/JCO.2006.09.4318","article-title":"Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users","volume":"25","author":"Decensi","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022060816053851900_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.breast.2005.11.011","article-title":"breast cancer TNM classification for treatment decision-making and research","volume":"15","author":"Veronesi","year":"2006","journal-title":"Breast"},{"key":"2022060816053851900_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10549-009-0504-0","article-title":"Mammary field cancerization: molecular evidence and clinical importance","volume":"118","author":"Heaphy","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"2022060816053851900_bib10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0002-9440(10)64879-1","article-title":"Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression","volume":"160","author":"Shaaban","year":"2002","journal-title":"Am J Pathol"},{"key":"2022060816053851900_bib11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10549-009-0534-7","article-title":"Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia","volume":"121","author":"Santisteban","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"2022060816053851900_bib12","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"2022060816053851900_bib13","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer","volume":"27","author":"Johnston","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022060816053851900_bib14","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060816053851900_bib15","article-title":"ALTTO (Adjuvant Lapatinib And\/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06\/N063D"},{"key":"2022060816053851900_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"key":"2022060816053851900_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cell.2006.12.023","article-title":"PTEN enters the nuclear age","volume":"128","author":"Baker","year":"2007","journal-title":"Cell"},{"key":"2022060816053851900_bib18","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.1158\/0008-5472.CAN-08-1740","article-title":"Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR\/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235","volume":"68","author":"Eichhorn","year":"2008","journal-title":"Cancer Res"},{"key":"2022060816053851900_bib19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2007.13.9949","article-title":"Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy","volume":"26","author":"Johnston","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022060816053851900_bib20","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1158\/0008-5472.CAN-06-2101","article-title":"Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers","volume":"67","author":"Xia","year":"2007","journal-title":"Cancer Res"},{"key":"2022060816053851900_bib21","first-page":"140","article-title":"Ductal carcinoma in situ: introduction of the concept of ductal intraepithelial neoplasia","volume":"11","author":"Tavassoli","year":"1998"},{"key":"2022060816053851900_bib22","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.2008.17.0829","article-title":"Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole","volume":"26","author":"Viale","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022060816053851900_bib23","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.2007.10.6393","article-title":"Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors\u2013International Breast Cancer Study Group","volume":"26","author":"Viale","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022060816053851900_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/PAI.0b013e3181f1da13","article-title":"A robust immunohistochemical assay for detecting PTEN expression in human tumors","volume":"19","author":"Sangale","year":"2010","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2022060816053851900_bib25","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060816053851900_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12253-008-9100-6","article-title":"Expression of ER, Ki-67 and cylinD1 in the pre-cancerous breast of Chinese patients","volume":"15","author":"Zhou","year":"2009","journal-title":"Pathol Oncol Res"},{"key":"2022060816053851900_bib27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-008-0161-8","article-title":"Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial","volume":"116","author":"Ellis","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"2022060816053851900_bib28","first-page":"961","article-title":"Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients","volume":"10","author":"Dowsett","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022060816053851900_bib29","first-page":"15s","article-title":"Randomized phase II trial of preoperative lapatinib versus placebo in HER2-positive breast cancer","volume":"28","author":"Decensi","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060816053851900_bib30","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1524-4741.2008.00642.x","article-title":"Potential of reduction in total tumor volume measured with 3D-MRI as a prognostic factor for locally-advanced breast cancer patients treated with primary chemotherapy","volume":"14","author":"Akazawa","year":"2008","journal-title":"Breast J"},{"key":"2022060816053851900_bib31","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djh166","article-title":"Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2-positive breast cancer","volume":"96","author":"Shou","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2022060816053851900_bib32","doi-asserted-by":"crossref","first-page":"7795","DOI":"10.1073\/pnas.0602468103","article-title":"A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer","volume":"103","author":"Xia","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060816053851900_bib33","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1158\/0008-5472.CAN-08-4490","article-title":"Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL","volume":"69","author":"Liu","year":"2009","journal-title":"Cancer Res"},{"key":"2022060816053851900_bib34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12094-009-0384-0","article-title":"mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb)","volume":"11","author":"Vazquez-Martin","year":"2009","journal-title":"Clin Transl Oncol"},{"key":"2022060816053851900_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jnci\/djn436","article-title":"Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice","volume":"101","author":"Strecker","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2022060816053851900_bib36","article-title":"Radiation therapy with or without trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy"},{"key":"2022060816053851900_bib37","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1200\/JCO.2007.14.0590","article-title":"Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer","volume":"26","author":"Gomez","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022060816053851900_bib38","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-007-9860-9","article-title":"Pooled analysis of diarrhea events in patients with cancer treated with lapatinib","volume":"112","author":"Crown","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"2022060816053851900_bib39","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2008.18.3285","article-title":"Effects of food on the relative bioavailability of lapatinib in cancer patients","volume":"27","author":"Koch","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/4\/8\/1181\/2250847\/1181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/4\/8\/1181\/2250847\/1181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T17:28:52Z","timestamp":1654709332000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/4\/8\/1181\/49840\/Lapatinib-Activity-in-Premalignant-Lesions-and-HER"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,1]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2011,8,3]]},"published-print":{"date-parts":[[2011,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-10-0337","relation":{},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,1]]}}}